BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

Retrieved on: 2025-06-12 15:15:54

Tags for this article:

Click the tags to see associated articles and topics

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal. View article details on hiswai:

Excerpt

BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline.

Article found on: www.benzinga.com